Sub-responders | Over-responders | ||||
Etiology of anemia/underlying disease | N | % | Etiology of anemia/underlying disease | N | % |
Polycythemia vera | 12 | 31.6% | Secondary erythrocytosis | 24 | 70.6% |
Megaloblastic anemia | 17 | 30.4% | Aplastic anemia | 8 | 40.0% |
Anemia of chronic disease | 10 | 29.4% | Hemolytic anemia | 3 | 21.4% |
β-thalassemic trait | 11 | 26.8% | Myelodysplastic syndromes | 46 | 17.7% |
Essential thrombocythemia | 11 | 17.7% | β-thalassemia major | 12 | 13.0% |
Iron deficiency anemia | 7 | 14.6% | Acute myelogenous leukemia | 3 | 12.5% |
Hemolytic anemia | 3 | 14.3% | Sickle-cell β-thalassemia | 2 | 8.7% |
Multiple myeloma | 10 | 12.7% | Chronic myelomonocytic leukemia | 5 | 8.5% |
Normal subjects | 5 | 10.2% | Multiple myeloma | 6 | 7.6% |
Acute myelogenous leukemia | 1 | 4.3% | Myelofibrosis | 2 | 6.2% |
Lymphoproliferative disorders | 6 | 3.7% | Iron deficiency anemia | 2 | 4.2% |
Myelofibrosis | 1 | 3.1% | Myeloproliferative disorders | 3 | 2.0% |
Myelodysplastic syndrome | 10 | 3.1% | Lymphoproliferative disorders | 2 | 1.2% |
β-thalassemia major | 2 | 2.2% |
|
|
|
Total | 106 | 9.8% | Total | 118 | 10.9% |
Diabetic patients | 48 | 45.3% | Diabetic patients | 6 | 5.1% |
Non-diabetic patients | 47 | 44.3% | Non-diabetic patients | 96 | 81.4% |
Unknown status | 11 | 10.4% | Unknown status | 16 | 13.5% |